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Available online 26 November 2015Understanding the pathogenesis of disease is instrumental in delineating its progression mechanisms and for
envisioning ways to counteract it. In the process, animal models represent invaluable tools for identifying
disease-related loci and their genetic components. Amongst them, the laboratory rat is used extensively in the
study of many conditions and disorders. The Rat Genome Database (RGD—http://rgd.mcw.edu) has been
established to house rat genetic, genomic and phenotypic data. Since its inception, it has continually expanded
the depth and breadth of its content. Currently, in addition to rat genes, QTLs and strains, RGD houses mouse
and human genes and QTLs and offers pertinent associated data, acquired through manual literature curation
and imported via pipelines. A collection of controlled vocabularies and ontologies is employed for the standard-
ized extraction and provision of biological data. The vocabularies/ontologies allow the capture of disease and
phenotype associations of rat strains and QTLs, as well as disease and pathway associations of rat, human and
mouse genes. A suite of tools enables the retrieval, manipulation, viewing and analysis of data. Genes associated
with particular conditions or with altered networks underlying disease pathways can be retrieved. Genetic var-
iants in humans or in sequenced rat strains can be searched and compared. Lists of rat strains and species-speciﬁc
genes and QTLs can be generated for selected ontology terms and then analyzed, downloaded or sent to other
tools. From many entry points, data can be accessed and results retrieved. To illustrate, diabetes is used as a
case study to initiate and embark upon an exploratory journey.
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1.1. Diabetes
The prevalence of diabetes, despite continuous efforts geared at un-
derstanding the underlyingmechanisms, the development of drugs and
improved care management, continues to grow. The prognosis of its
worldwide increase and the economic and healthcare burdens that ac-
company it, offer a somber picture. There are two major types of diabe-
tes mellitus: type 1 diabetes mellitus (T1D) which results from the self-
destruction of insulin producing pancreatic beta cells and represents
~10% of all cases and the more prevalent type 2 diabetes mellitus
(T2D) of complex and still elusive etiology featuring both impaired
insulin secretion and resistance/decreased sensitivity in target tissues.
The defective insulin secretion, exhibited by both diabetes types albeitRoad, Milwaukee 53226, USA.
61 (cell).
on behalf of the Research Network ofto varying degrees, affects glucose homeostasis. The hyperglycemic
state—a hallmark of the condition, underlies a range of complications
that affect the kidney, the eye, the cardiovascular systems and other
organ systems. Genetic factors are likely involved but the quest for
major culprit genes, particularly for T2D, has not been very fruitful.
However, high-throughput experiments are broadening the range of
potential players. Environmental factors such as diet and lifestyle are
known to be important contributors. Evidence is accumulating for
the impact of non-coding RNAs, epigenetics and the microbiota have
in the complex network of diabetes etiology. A small percentage of
diabetes is monogenic and is manifested early in life; defects affect the
production/processing of insulin precursor. T2D, the major form of
diabetes mellitus, once considered a condition of adult age, is in-
creasingly affecting younger people [1–6]. Pharmacologically, drugs
that prompt insulin release by blocking the ATP-sensitive potas-
sium channels, such as nateglinide and repaglinide or metformin, an
antihyperglycemic drug, are among the agents that are currently used.
Metformin mode of action is thought to involve the activation of aden-
osine monophosphate-activated kinase (AMPK) signaling pathway, anComputational and Structural Biotechnology. This is an open access article under the CC BY
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primary target; the mitochondrial respiratory chain complex I appears
to be themainmetformin target but themolecularmechanisms of its in-
hibition are not well understood. [7–9].
1.2. Balancing Glucose Levels: Insulin and Glucagon Secretion and Signaling
The pancreatic beta and alpha cells of the islets of Langerhans
produce and release insulin and glucagon, respectively—two hormones
essential for maintaining proper levels of glucose. When glucose levels
are high, insulin is released to prompt glucose uptake in the muscle,
heart and adipose tissues. Glucagon has the opposite effect: it promotes
glucose release from liver storage by stimulating glycogenolysis and
gluconeogenesis while inhibiting glycolysis and glycogenesis. Both
hormones are expressed as precursors that need to be processed before
they can engage their receptors. The mechanisms of glucagon release
are incompletely understood. Once released, it can bind the glucagon
receptor—a G-protein coupled receptor (GPCR) that activates the
Galphas (Gs) type of heterotrimeric G protein. The subsequent activa-
tion of adenylyl cyclase and production of cyclic AMP (cAMP) sets in
motion the protein kinaseA (PKA) signalingpathway. PKA signaling im-
pacts a broad range of processes in a tissue- and cell-speciﬁc manner. In
the context of glucagon, it underlies the glucagon-mediated effects on
glucose levels. In contrast to glucagon, insulin secretion is a better un-
derstood regulatory network, especially theﬁrst phase of its biphasic re-
lease mode. When present, glucose is rapidly taken up by the beta cells
and its oxidative metabolism leads to an increase in the ATP/ADP ratio
which in turn triggers closure of ATP-sensitive potassium channels
(KATP) leading to membrane depolarization and opening of voltage-
gated calcium channels (VDCC). The rise in calcium concentration
promotes fusion of insulin-granules with the plasma membrane. The
initial and rapid release phase involves granules at or near the plasma
membrane. The second, slower but sustained release phase, is less
well understood but it may involve factors resulting from pyruvate cy-
cling in the course of glucose metabolism. Both phases of insulin secre-
tion are impaired in T2D. Once released, insulin binds the insulin
receptor—a receptor tyrosine kinase (RTK) that modulates a range of
substrates to activate two downstream signaling cascades. The phos-
phatidylinositol 3-kinase-Akt (PI3K-Akt) and the Raf/Mek/Erk MAPK
pathways mediate the very large spectrum of insulin actions. In
insulin-sensitive tissues, insulin signaling via PI3K-Akt stimulates
the membrane localization of insulin responsive glucose transporter
GLUT4 (SLC2A4 gene) to induce glucose uptake. Both PI3K-Akt and
Raf/Mek/Erk intracellular cascades have numerous cytoplasmic and
nuclear targets and impact a broad range of cellular processes. In the
brain insulin, along with leptin, leads to increased expression of
appetite-decreasing and reduced expression of appetite-stimulating
genes. Impaired insulin signaling could have the opposite effect. Insulin,
glucagon, other preproglucagon derived peptides, islet and/or gut hor-
mones and the nervous systemmediate the nutrient sensing, responses
and energy expenditure outcomes [10–17].
1.3. Glucose Uptake
Glucose uptake in the insulin responsive tissues is mediated by
the product of SLC2A4 gene, GLUT4. In the basal state, the transporter
is sequestered in specialized vesicles that cycle/recycle between various
compartments. Insulin signaling, described above, activates two down-
stream intracellular cascades, of which PI3K-Akt via AKT2—one of the
three Akt members, modulates the activity of Rab proteins. The Rab
family of small monomeric G-proteins regulates vesicular trafﬁcking.
Their function is modulated by the guanine exchange factors (GEF)
that promote GDP to GTP exchange and the GTPase activating proteins
(GAP) that promote GTP hydrolysis, to prompt or inhibit their activity,
respectively. Potential GAPs, such as TBC1D4 (known as AS160), are
substrates for AKT2; TBC1D4 phosphorylation by AKT2 inactivates it,thus terminating the inhibitory effect this GAP exerts upon Rab activity.
Rho represents another family of small G proteins that regulate the cy-
toskeleton. Rac1 member, downstream of PI3K but independent of Akt,
is involved in the trafﬁcking of the transporter. Both arms of the trans-
port pathway—the Akt-dependent and the Akt-independent, are neces-
sary for proper trafﬁcking. In adipocytes, insulin stimulated GLUT4
uptake involves another Rho member—Rhoq; it does not require PI3K
but is dependent upon formation of a Rhoq activating complex down-
stream of insulin-stimulated insulin receptor [18,19].
Reduced insulin-stimulated glucose transport is observed in T2D
patients and animal models such as the obese Zucker rat. While in
these cases, the impaired glucose transport is independent of GLUT4
expression, other models show reduced levels of GLUT4 in adipose
tissue and skeletal muscle. The streptozotocin-induced diabetic rat, an
experimental model of diabetes, shows insulin resistance and reduced
Glut4 protein expression in skeletal and cardiac muscle, also seen in
the Goto–Kakizaki rat model [20,21]. Differential epigenetic inputs can
result in varied levels, absence or presence of transcripts. Differential
miRNA (microRNA) contributions can impact the level of protein
products [4,5]. Expression of Glut4 in skeletal muscle is regulated by
the activities of calcium/calmodulin dependent kinase 2 (CAMKII) and
also by adenosine monophosphate-activated protein kinase (AMPK)
and calcineurin-mediated signaling [22]. How a high-fat diet/obesity
impacts on Glut4 expression and/or translocation and activity and, in a
broader sense, on the lack of adequate insulin response in the presence
of high glucose, at themolecular level, remains to be resolved. Obesity is
a known risk factor in the development of T2D. Overexpression of Glut4
in the adipose and skeletal muscle tissues of transgenic mice improves
insulin-stimulated glucose uptake and diminishes the insulin resistance
exhibited in T2D and obese states [21].
1.4. The Versatile Glucose
Glucose, the six-carbon sugar,maynot be as potent an energy source
as the larger fatty acidsmolecules, but is amajor and the primary fuel of
the brain and a versatilemolecule overall. A small percentage of glucose
is used in the hexosamine biosynthetic pathway. Its major product,
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is used for
theO-GlcNAcylation ofmany cytoplasmic and nuclear proteins. The ser-
ine and threonine glycosylation sites can also be phosphorylation sites
by serine/threonine kinases. The high incidence of O-GlcNAcylation
and its interplay with phosphorylation modulates many physiological
processes and plays a role in the etiology of diseases that includes
diabetes, cardiovascular and neurodegenerative conditions and cancer.
Hexosamine biosynthesis engages glucose, amino acid, fatty acid, and
nucleotide metabolism and as such is considered a nutrient sensor. Its
role in pancreas development and beta-cell physiology coupled with
the high levels of enzymes and modiﬁed proteins underlies the poten-
tial role it has in diabetes. Increased levels of O-GlcNac levels appear
to be involved in insulin resistance and diabetes development [23,24].
An alternate route of glucose oxidation is the pentose phosphate
pathway (PPP), also known as the pentose phosphate shunt. The initial
oxidative branch produces NADPH necessary for antioxidant and
anabolic pathways and other essential cellular systems. The non-
oxidative branch produces ribose 5-phosphate, required for nucleic
acid synthesis. Given the range of cellular demands for NADPH, the im-
portance of glucose-6-phosphate dehydrogenase (G6PD), the ﬁrst and
rate-limiting enzyme in the PPP, is not surprising. Studies show de-
creased G6PD activity, in many tissues, resulting from hyperglycemic
or diabetic states. Decreased G6PD activity in the kidney cortical cells
of streptozotocin-induced diabetic rats and decreased beta cell survival
in mouse and human islets have been reported [25].
The main product of glucose oxidation—pyruvate—is at the cross
roads of pathways important for glucose and energy homeostasis. Its ir-
reversible decarboxylation to acetyl-CoA can fuel the tricarboxylic acid
cycle or be used for fatty acid biosynthesis. Pyruvate shuttling to and
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oxaloacetate (OAA) conversions. Pyruvate cyclingmay play a role in the
second phase of insulin secretion. The pyruvate cycle is perturbed in
models of T2D and dysfunctional islets, such as the prediabetic Zucker
diabetic fatty (ZDF) rats [26].
Given the range of hormonal actions and the critical role of glucose
homeostasis and its relationship to energy and cellular homeostasis,
the complexity of the diabetic condition and the difﬁculty of deciphering
its routes at the molecular level are of no surprise. In the following sec-
tions pertinent information available at RGD is investigated, existing or
newer directions are presented, possible ramiﬁcations are discussed.
2. Materials and Methods
RGD runs on an Oracle database. The tools built by RGD use J2EE
technologies and they can be run in any Java container implementing
Java Servlets and Java Server Pages. Applicationweb development relies
on Spring's model-view-controller (MVC). User interface relies on Ajax
and Javascript and Cascading Style Sheets (CSS). Pathway diagrams are
built with Pathway Studio software package from Elsevier, version 10.
Pathway diagram pages are built via a web application speciﬁcally de-
veloped at RGD [27, see also 29, 31, further down].
3. Results and Discussion
3.1. Starting the Journey
3.1.1. Entry Points—Disease and Pathway Portals
There are several entry points on the main homepage of RGD to ac-
cess data for topics of interest, here diabetes. Disease and Pathway
Portals look like good choices to start the journey [Fig. 1, highlightedFig. 1.RGDhomepage. Themain homepage of RGDwith the various entry points. TheDisease a
the Phenotypes andModels portal, and the CustomRats entry, are highlighted in yellow. Disease
tabs at the top of the page.in red]. “Diseases”, currently home to nine portals, includes cancer,
cardiovascular, diabetes, immune and inﬂammatory, neurological,
obesity/metabolic syndrome, renal, respiratory and sensory organ
[28]. For each portal, the disease data option is the default. The other
options include phenotypes, biological processes, pathways, tools,
related links and rat strain models. For any option one can select vocab-
ulary/ontology terms from a broad category and then select any of the
more speciﬁc terms within the broader category. For each selection, a
summary table shows the total of annotated objects—genes, QTLs and
strains, by species, as applicable. Itemized lists of genes and QTLs for
rat, human and mouse, and for rat strains are displayed. Every entry
links to its corresponding report page in RGD. A Genome Viewer
(GViewer) offering a genome-wide view of annotated rat genes, QTLs
and strains, and an overview of Gene Ontology (GO) annotations across
the three vocabularies of GO are also present. In Fig. 2, a selection is
made for the category ‘Diabetes Mellitus’ and for the disease term
‘type 2 diabetes mellitus’, and the results are shown. As mentioned,
there is a range of complications associated with diabetes affecting var-
ious systems. They can be found in the diabetes portal, under the cate-
gory ‘Diabetes Complications’ as well as in the portals dedicated to
those systems.
The Pathway Portal offers a collection of interactive diagram pages
organized by the ﬁve major nodes of the pathway ontology (PW):
classic metabolic, signaling, regulatory, disease and drug pathways. In
addition, there are terms and associated diagrams for the altered
version(s) of pathway(s). A disease pathway is viewed as the intersec-
tion of altered pathways converging into the disease phenotype [29,
30]. Many, if not most, of the pathways of glucose metabolism have in-
teractive diagram pages while others are dedicated to insulin secretion,
insulin and glucagon signaling and the downstream cascades they acti-
vate, glucose uptake, altered pathways relevant to T2D, the T2D diseasendPathway Portals, and the Function options are highlighted in red; theGenome Tools and
s and Pathways options, and theGenome Tools, are accessible from both the icons and the
Fig. 2. Example of a disease portal query. A result using theDiabetes Disease Portal, speciﬁcally looking for type 2 diabetesmellitus in the diabetesmellitus category, showing the summary
of annotated objects on the top, followed by GViewer, the itemized lists of annotated objects and a partial view of Gene Ontology overview.
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of several drugs used in T2D treatment. The portal also offers pathway
suites and suite networks. A pathway suite or suite network offers an in-
stant snapshot of pathways connected within a broader context or of
suites that are inter-related, respectively. For instance, the two pathway
suites within the glucose homeostasis pathway suite network are for
the glucose-related regulatory and signaling pathways and for the me-
tabolism of glucose and related molecules, respectively. They are differ-
entially highlighted in the overall representation. Each entry within the
two suites links to that individual diagram page [Fig. 3].
3.1.2. Tools
RGD offers a collection of tools, most built-in-house, to allow for the
retrieval, visualization and analyses of data [31]. The ‘Genome Tool’
entry point [Fig. 1, highlighted in yellow] presents a succinct descrip-
tion of them with links to the sites [Fig. 4]; some will be used as entry
points, others during the more involved, exploratory leg of the journey.
The ‘Phenotypes &Models’ portal provides rat phenotype and rat strains
and disease models data and also contains the PhenoMiner database
which houses quantitative records of phenotype data [see Fig. 1,
highlighted in yellow]. Video tutorials are available for help with
how to use several of these tools. The growing collection of videos is
available from themain homepage of RGD. A recently added video tuto-
rial is for the “Object List Generator & Analyzer” OLGA tool; the tool will
be used during the exploratory step of this journey.
3.1.2.1. Genome Tools—GViewer. The ‘Function’ entry point [see Fig. 1,
highlighted in red] and GViewer in Genome Tools [see Fig. 4], both
allow for ontology searches to retrieve results for terms of possible
interest and their associated annotations using user-selected keywords.
A ‘Function’ result will show a summary of the number of terms thatmatch a given keyword in each ontology andwhether there are annota-
tions. Once a selection is made, that particular ontology can be searched
in the ontology browser. In GViewer one can search all (default) or
a subset of ontologies. The result will return the objects and the
term(s) they are annotated to containing the keyword(s) used in
the query, along with a genome-wide view (GViewer) of rat genes,
QTLs and strains annotated to those terms and their chromosomal
association. For instance, typing ‘insulin’ in the search box with the
default option of all, brings up over 1100 genes, some 250 QTL and 9
strains (genes are colored brown, QTLs are in blue, strains in green).
One can ‘glide’ along individual chromosomes by clicking on one, and
move along its length. A zoom pane will open showing the objects in
the areas ‘scanned’ horizontally, where one can zoom in and out, access
the individual report pages for the objects within by clicking on them,
go to the Genome Browser (GBrowse) for more options, or close the
pane. [Fig. 5]. Report pages can also be accessed from the tabular list
of objects located below the GViewer (and the pane, if opened) or by
right clicking on the object in theGViewer. In addition to viewing the re-
port page, the right click also gives the options to access the object in
GBrowse or to remove it from the GViewer display. The tool also offers
the option of adding search terms using Boolean operators (default is
OR). Selecting ‘glucose’ for instance, with the AND operator keeps the
list still fairly large, as expected. One could do the same search(es) but
select for ontologies related to clinical phenotype, such as the clinical
measurement ontology (CMO), the measurement method ontology
(MMO) or the experimental condition ontology (XCO). However, in
these cases, it would be interesting to view the quantitative phenotype
data, using the PhenoMiner.
3.1.2.2. PhenoMiner. The PhenoMiner database, at ‘Phenotypes &Models’
[Fig. 1, highlighted in yellow], is speciﬁcally designed to integrate rat
Fig. 3.Glucose homeostasis pathway suite network. The glucose homeostasis pathway suite network, partial view. A graphical overview and short description are on top of the page. From
within each pathway suite, the individual diagram page(s) can be accessed by clicking on their image(s), the title or the underlined ‘click here’ option.
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studies—http://rgd.mcw.edu/phenotypes/ [32,33]. PhenoMiner can be
queried using one or a combination of several ontologies/controlled vo-
cabularies, developed at RGD, some speciﬁcally designed for the
PhenoMiner project [34]. The four ontologies/vocabularies for querying
the database are: CMO, MMO, XCO and Rat Strain (RS) [Fig. 6A and
inset]. CMO—the clinical measurement ontology is developed to incor-
porate terms for what is actually being measured, e.g., circulating me-
tabolites, organ/tissue measurements, including diseased organ/tissue
measurements; MMO—the measurement method ontology is devel-
oped to incorporate terms for the method used to make the measure-
ment, e.g., radiotelemetry, radioimmunoassay; XCO—the experimental
condition ontology is being developed to incorporate terms pertinent
to the condition(s) of the experiment for which the measurement is
done, e.g., elements in the diet, in the environment. In the example,
CMO is used to ﬁnd terms associated with insulin or glucose levels or
for terms pertinent to pancreatic islet cell measurement by selecting
‘bloodmeasurement’ or ‘organmeasurement’ nodes and navigating fur-
ther down. For instance, by expanding the ‘blood chemistry measure-
ment’ child term, one can see the various terms for glucose levels or
those under blood hormone/blood peptide level for insulin or other hor-
mones [Fig. 6B and C]. The number of records for each term is shown in
parentheses to the right of terms. The results can be further narrowed
by selecting terms from the other vocabularies or they can be viewed
by requesting the report. Results are shown graphically and also within
a table, which can be downloaded or viewed in expanded mode for ad-
ditional details [Fig. 7 and inset]. From the expanded view one also has
the option to access the references for results of interest, such as those
associated with glucose levels in the Goto–Kakizaki (GK) derivedstrains. GK is an extensively used model for T2D [35]. Congenic strains
carrying segments of GK chromosome 1 in the F344 normoglycemic
background are established; QTLs deﬁne regions on chromosome 1 as-
sociated with defective insulin secretion and with signs of insulin resis-
tance. The impaired insulin secretion locus on rat chromosome 1 is
conserved across species; syntenic regions harbor T2D candidate
genes such as the human TCF7L2 or mouse Sorcs1. Niddm35 (non-insu-
lin dependent diabetes mellitus rat QTL 35) and the short Niddm36
(non-insulin dependent diabetesmellitus rat QTL 36) covering a contig-
uous region of chromosome1 and overlapped byNiddm43 (non-insulin
dependent diabetes mellitus rat QTL43), are amongst the loci in the re-
gion [36–39]. At this point, perhaps one should embark on an explorato-
ry journey, using the QTLs and the candidate genes as starting points, to
navigate resources and tools at RGD, accompanied by the available liter-
ature and bearing in mind the various aspects of glucose homeostasis
along with the roles of epigenetics and of non-coding elements, as
they likely combine in the complex etiology of T2D and of diabetes in
general.
3.2. An Exploratory Journey
3.2.1. From QTL to Genes, Using the OLGA Tool
The three diabetes-associated rat QTLs identiﬁed above using the
PhenoMiner tool: Niddm35 and Niddm36 occupy adjacent regions of
rat chromosome 1 whose span is overlapped by Niddm43, which also
overlapsmany other QTLs. Of these, a substantial number are associated
with glucose and lipid levels, body weight and renal function followed
by those associated with blood pressure, cardiac and bone features.
Also present, are several tumor susceptibility QTLs. A great number of
Fig. 4.Genome Tools. The list page of currently available tools, eachwith a brief description and link to the individual tool page. The page can be accessed from ‘Genome Tools’ entry on the
main homepage.
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data can be accessed by selecting the ‘QTLs in Region’ and ‘Genes in Re-
gion’ options available in the QTL report pages, the ‘Object List Genera-
tor & Analyzer’ (OLGA) tool [see Fig. 4] offers a variety of querying and
data manipulation options. Lists of rat, human and mouse genes or of
QTLs and rat strains can be generated using one of several options; for
instance, ontology term or genomic region. The lists can then be used/
combined with intersection, union or subtraction options; the resulting
list can be downloaded or sent to other tools for further analysis. In
Fig. 8, the QTLs Niddm35 and Niddm43 were chosen and the generated
gene lists were used in conjunction with the union option. The new list,
containing 1,428 unique genes, was then intersected with the list of
genes generated for the T2D term in the disease ontology, containing
331 genes. The resulting set contains 18 genes and several options are
available for its further use; the set can be downloaded for later analysis
or sent directly to other tools, such as the Gene Annotator (GA) or the
Variant Visualizer [Fig. 8, upper frame]. In the GA tool one can look up
the available annotations for any or all the ontologies as well as informa-
tion available in other databases. Variant Visualizer lets one choose one or
all sequenced rat strains [40,41], and select parameters (default is all) to
return variant data. Both tools will be used as the exploration continues.
3.2.2. A Set of Genes
A quick inspection of the function/process and pathway involve-
ment of the eighteen genes using the GA tool, shows a spectrum of bio-
logical roles. It has to be mentioned here that ontology-based results
incur a bias if genes happen not to be annotated to queried
terms—genes may not be annotated because there is no available data
in the literature, because data is suggestive but not conclusive enough,
or because in the curation process, the genes have not yet been targeted(RGD targets genes based on their disease association for portal
speciﬁc conditions and relevant pathways). Of the two genes men-
tioned earlier—TCF7L2 and Sorcs1, only rat Tcf7l2 is on OLGA's result
list, as only Tcf7l2 has a T2D annotation. It is likely that for Sorcs1 there
is little data in the literature; inspection of Gene Ontology (GO) annota-
tions shows that there is a paucity of them for this gene across the
three species. Sorcs1 is not annotated to T2D but it is a candidate gene
for the QTL Niddm65 (non-insulin dependent diabetes mellitus QTL
65), which is annotated to T2D and resides within the species-
conserved region of GK strain chromosome 1 associated with T2D
susceptibility. Themouse Sorcs1 gene is spanned by several QTL, includ-
ing the ‘type 2 diabetesmellitus 2’, T2dm2_m. Note that T2dm2_m (and
other diabetes related mouse QTLs) has the disease in its name. Mouse
phenotype annotations, using themammalian phenotype (MP) ontolo-
gy, for both the gene and the QTL weremade by the Mouse Genome In-
formatics (MGI) database and imported via the mouse MP pipeline.
Of the 18 genes, several have a role in drug transport and metabo-
lism (Abcc2, Cyp2e1 and Gstp1), two are the insulin genes (there are
two in rodents) or the insulin-like growth factor (Igf2), others are in-
volved in lipid and vitaminmetabolism (Cpt1a, Bscl2 and Rbp4), histone
modiﬁcation (Sirt3) or, like Tcf7l2, play a role in transcription (Esrra).
Interestingly, some have a role in the nervous system such as Gal—the
ligand for galanin receptor, involved in action potential, the adrenergic
receptor Adra2a, or Ide—the insulin degrading enzyme, which also de-
grades glucagon and the amyloid beta peptide underlying the pathoge-
nicity of Alzheimer Disease. Most genes are implicated in a range of
conditions that collectively, in addition to T2D, include obesity, cardiac
and vision disease, heart and kidney failure, neurodegenerative disease
and various cancers. Perhaps, the time is ‘ripe’ to investigate the TCF7L2
gene story in more detail.
Fig. 5. Genome Viewer (GViewer). A GViewer result for ‘insulin’ keyword search, showing the zoom pane for ‘gliding’ along chromosome 1.
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TCF7L2 is a transcription factor and a major effector of the beta-
catenin dependent pathway of Wnt signaling, known as the canonical
pathway. In the absence of a Wnt signal, beta-catenin is sequestered
into the cytoplasm by a ‘destruction complex’ phosphorylated and
targeted to degradation. Wnt signaling promotes destabilization of the
destruction complex; beta-catenin can then translocate to the nucleus
to displace repressors from the Tcf/Lef effector complex and recruit a
number of co-activators. Alterations in components of the pathway
have been implicated in several conditions, primarily tumorigenesis
and bone malformation. The range of Wnt target genes is rather large
which is not surprising given the many roles the pathway plays in em-
bryonic development, tissue regeneration, cell polarity, proliferation
and cell fate determination [42—the interactive diagram page for Wnt
signaling, canonical pathway, has tabular views of its genes and their in-
volvement in diseases and pathways, direct link to the diagram page for
its altered version, references and graph path view]. Studies in rodent
and human pancreatic islets, show that TCF7L2 directly and indirectly
impacts on a transcriptional network important for the proper mainte-
nance of beta cell and the production of insulin. Primarily via ISL1 (islet
1) transcription factor, it regulates downstream effectors that include
transcription factors, proinsulin processing enzymes PCSK1 and
PCSK2, and SLC30A8 (ZnT8) zinc transporter. The transcription factors,
which include MAFA, PDX1, NKX6-1 and also NEUROD1, are known
for their roles in the maintenance of beta cells and insulin biosynthesis
[43,44]. SLC30A8 (ZnT8) is almost exclusively, and also abundantly,
expressed in the islets of Langerhans, and is associated with insulin
secretory granules. Zinc is essential for the formation of proinsulin
hexamers which in the immature secretory granules will be processed
into zinc–insulin hexamers, characteristics of the mature granule. Poly-
morphisms in the transporter gene differentially inﬂuence T2D with
both increased and decreased disease risk [45,46].The gene report page for the human TCF7L2 gene shows disease
annotations to T2D as well as to gestational diabetes, diabetic nephrop-
athies, insulin resistance and pancreatic neoplasms disease terms and
to pancreatic cancer pathway term. In addition, there are several other
cancer pathway annotations based on annotations from KEGG pipeline
[29]. T2D annotations are also imported from NCBI's ClinVar and
OMIM via dedicated pipelines. Looking up the human variants from
ClinVar Clinical Variants section under Sequence category on the gene
report page, one can see that there are several copy number loss or
gain variants, and some single nucleotide polymorphism (SNP) variants.
Most are categorized as pathogenic or likely pathogenic, for phenotypes
unrelated to T2D, few (the SNPs) are categorized as T2D risk factors.
Choosing the coordinates of rat Tcf7l2 and all sequenced strains in
Variant Visualizer with the default parameter options (all) shows that,
except for two variantswhich are exonic (and synonymous), all variants
are outside exons and there are many insertion/deletions, as evidenced
by the presence of numbers/minus signwithin the colored boxes (a col-
ored box indicates a difference from the reference position) [Fig. 9 and
inset]. Insertion/deletions can change the reading frame and non-
exonic variants can affect splicing. There are several transcripts of the
human gene, with alternative splicing producing a number of isoforms.
Alternative splicing of the human TCF7L2 gene exhibits both general and
tissue-speciﬁc features, the latter including the pancreatic islets where
transcripts containing exon4 are at twice the level observed in other tis-
sues. The alternative exon4 is one of several alternative exons in TCF7L2;
interestingly, the T2D risk allele is intronic [47].
3.2.4. Downstream of TCF7L2
Asmentioned, in the pancreatic islets TCF7L2 directly regulates ISL1,
a member of the LIM/homeodomain family of transcription factors, and
impacts further downstream the MAFA, PDX1, NKX6-1 and NEUROD1
transcription factors, the proinsulin processing enzymes PCSK1 and
AB
C
Fig. 6. Phenotypes &Models, PhenoMiner. An overview of Phenotypes andModels showing the entry point to PhenoMiner database (A and inset), themain nodes in CMO (B) and expan-
sion of selected nodes to view more speciﬁc terms (C).
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essential roles in the formation and maintenance of mature beta cell
function and the expression of the insulin gene. Chronic exposure to
glucose, possibly exerting an oxidative stress effect, affects the expres-
sion and/or DNAbinding activity of PDX1 andMAFA, an effect alleviated
by antioxidant treatment [44]. Checking the disease annotations for
Pdx1 and Neurod1 genes in the database, one ﬁnds manual annotations
to T2D, aswell as glucose intolerance and insulin resistance, hyperglyce-
mia and obesity. Nkx6-1 has one disease annotation to spinal cord inju-
ries, and the human gene is a candidate gene for GLUCO232 (glucose
level QTL 232). Mafa genes do not have disease annotations. All four
transcription factors have KEGG annotations to the ‘maturity onset
diabetes of the young pathway’ term, while Pdx1 and Mafa are also
annotated to the T2D pathway. Interestingly, NEUROD1 and possibly
PDX1 may have a role in the transcription of MIR-375—a microRNA
associatedwith pancreatic function [48]. PDX1may exert upstream reg-
ulatory roles whereas NEUROD1 interacts with both upstream and
downstream conserved sequences. The promoter region of MIR-375
contains binding sites for ONECUT1, (also known as HNF6) and INSM1
transcription factors, both important for the development of pancreatic
islets. Of the two genes, Onecut1 is associated with the maturity onset
diabetes of the young pathway (KEGG pipeline) and both appear to be
involved in pancreatic islet function.What is the role of Mir-375 and of non-coding RNA molecules in
general, in the context of pancreatic islet function or dysfunction, insulin
and associated glucose homeostasis?
3.2.5. Non-Coding RNA and the Islet Cells
It is now known that the genome is pervasively transcribed and that
non-coding RNAs exert important regulatory roles. The microRNAs
(miRNAs) generally inhibit the translation of target genes, while the
long non-coding RNAs (lncRNAs) span a range of regulatory functions
[49–51].
3.2.5.1. miRNAs.Mir375, speciﬁcally expressed in islet cells, is believed
to play a role in the early stages of islet development, particularly as
the embryonic stem cells differentiate into liver and insulin secretory
cells [48]. Mir375 is also involved in regulating insulin expression and
secretion. AndMir375 is one of a number of miRNAs involved in insulin
synthesis and secretion (for instance Mir9 and Mir29a/b/c), insulin
sensitivity in target tissue (Mir143 and Mir29) or glucose and lipid
metabolism (Mir103/107 and Mir122) and thus, having potential roles
in diabetes [see for instance, 52,53]. Several, including Mir375, are dif-
ferentially expressed in T2D patients and rodent models such as the
obese diabetic mouse and the GK rat.
Fig. 7. PhenoMiner report. The PhenoMiner report for ‘calculated blood glucose level’ term and a view of the expanded table in the inset.
Fig. 8. Object List Generator & Analyzer (OLGA). OLGA result list for the union of QTLs Niddm35 and Niddm43 intersected with Type 2 Diabetes Mellitus and the options available for its
further analysis or download.
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Fig. 9. Variant Visualizer. Results for Tcf7l2 in Variant Visualizer with all strains selected and the default parameter options (all); the inset shows the two exonic variants in the GK strain.
44 V. Petri et al. / Computational and Structural Biotechnology Journal 14 (2016) 35–48miRNAs can have a large number of mRNA targets and a single
mRNAmay be the target ofmanymiRNAs; the number of predicted tar-
gets is indeed very large. However, experiments continue to increase
the number of validated targets, thus helping to delineate the regulatory
realm of individual miRNAs. Validated and predicted mRNA targets for
human, mouse and rat miRNAs can be found at the miRGate database
[54], and now in RGD.
A newly added feature at RGD, is themiRGate data import. Users can
search for the miRNA of interest across the three species, then scroll
down the gene report page to the Genomics section where the miRNA
Target Status option is located. Clicking on the option displays the
results—if there are validated targets, those are displayed; a tabular
report for all targets is also available and the detailed report can be
downloaded in several formats. The results for the human MIR375 are
shown [Fig. 10 and insets]. The only validated mRNA target of rat
Mir375 is Pdk1, also validated for the human and mouse microRNA
375. In addition, the larger list of mRNA targets of mouse miR-375 is
comparable to the human list, in terms of gene. This is reassuring as
it points to a comparable, and conserved, miRNA regulatory network,
despite the differences between the cell composition and the spatial
architecture of human and rodent—mouse and rat islets are the two ex-
tensively usedmodels of pancreatic function and functional failure. As a
note, the human islets comprise ~50% beta, ~40% alpha and ~10% delta
cells, the remainder being epsilon and PP cells, with a random-like dis-
tribution. In contrast, rodent islets are 60–80% beta, found in the core
and surrounded by 15–20% alpha cells in a mantle fashion [55].
The reciprocal miRNA information for the genes, which miRNA tar-
gets them, is similarly available on the gene report page. Only mouse
Tcf7l2 has a validated miRNA for which it is the target—Mir210, which
has only a human ortholog currently displayed in RGD.
3.2.5.2. lncRNAs. Long non-coding RNAs, by deﬁnition larger than 200
nucleotides but many times spanning very large regions have been
assigned a spectrum of regulatory roles, from transcriptional regulation
with both activating and repressive inputs, to scaffolding andarchitectural determinants, chromatin dynamics, epigenetics, higher-
order chromosomal organization [56]. An inventory of the human beta
cell transcriptome indicates that islet lncRNA are tissue-speciﬁc and
also stage-speciﬁc. While some locate in genomic regions devoid of
protein-coding genes, others map to regions of protein-coding genes
important for beta cell function, many in divergent, antisense, orienta-
tion [57]. Interestingly, some are differentially expressed if cells have
been exposed to increasing glucose concentration (HI-LNC78, and 80, of-
ﬁcial nomenclature TUNAR and OLMALINC, respectively); others are ab-
errantly expressed in the islets of T2D donors. As expected, glucose
exposure also increases the expression of genes involved in insulin de-
pendent function/responses, including insulin (INS) itself.
Inspection of RGD entries for the two human lncRNAs cited above,
reveals that there is little data available. Perhaps not surprisingly,
inspection of QTLs in the regions reveal that they are associated with
glucose levels and body weight, and in the case of TUNAR, also with
insulin and leptin levels. Interestingly, there are also tumor related
QTLs in these regions: prostate tumor susceptibility for both lncRNAs,
also mammary tumor susceptibility for TUNAR. Of the two, only
TUNAR has an ortholog in the mouse system. However, sequence simi-
larity may not be a particularly stringent requirement for lncRNA func-
tion if the secondary/tertiary structural features are preserved. Unlike
the protein coding genes, dependent on the three-letter amino acid
speciﬁcation of codons for conserved peptide composition, dictating
the structure and subsequent function of the protein, the folding of
non-coding RNA is dependent on whether base-pairing is thermody-
namically favorable, rather than the identity of the nucleotide.
The high tissue speciﬁcity of coding and non-coding islet genes has
to be tightly linked to the chromatin organization of those loci, and
thus to the epigenetics that control them. Indeed, the CpG islands of
INS in non-insulin producing cells (most others) are methylated and
therefore do not express insulin; they are demethylated in the insulin-
producing pancreatic islet beta cells [5 and references within]. With
the genetic components of T2D being so elusive, perhaps some of the
contributions to and/or susceptibilities for the condition rise from an
Fig. 10. A miRNA gene report page. The report page for the human MIR375 gene; the insets show the validated targets and the overall target information.
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evidence for it, and if so, what might be the mechanisms?
3.3. Epigenetics and Diabetes
Epigenetic changes which involve the modiﬁcation and remodeling
of chromatin, are heritable and independent of DNA sequence, and
they play a key role in the differential expression of genes. The methyl-
ation of DNA at cysteine residues (CpG) and the many ways in which
the histone tails are modiﬁed represent the modiﬁcation route; the
remodeling route is dependent on four protein complexes representing
four distinct pathwayswhich can space, slide or reposition entire nucle-
osomes as well as insert or evict histones, in an ATP-dependent fashion.
All, are components of one of the suites within the ‘Gene Expression
and Regulation Pathway Suite Network’ [58] in the ‘RGD Pathway Suites
and Suite Networks’ collection; this suite network has been recently
updated.
The differential methylation of the insulin gene has beenmentioned
[5]. As the promoter of INS is highly methylated in all other cells except
the islet beta cells, the death of beta cells will lead to its components,
such as unmethylated INS, to be present in the circulatory system. De-
tection of unmethylated INS in the circulation could be a means to as-
sess beta cell death resulting from normal turnover of the cells or
possibly, as is in the case of T1D, aberrant cell death. This approach
has been used in mouse models of T1D. Aberrant methylation in islets
from T2D donors versus healthy individuals, as well as in skeletal mus-
cle and adipose tissue is observed, although it is not clearwhether this is
the result or the cause of the condition. Single nucleo-
tide polymorphisms (SNPs) from T2D donors that either remove or in-
troduce a CpG site, are also reported [59] Many studies haveaddressed the issue of DNA methylation and changes from its regular
patterns in diabetes, but histone modiﬁcation and its aberrant pheno-
type in diseases, including diabetes, is also reported. Metabolism/diet
can affect epigenetics via provision of donor groups; for instance, the
methyl group via the methionine cycle, the UDP-GlcNAc via the
hexosamine pathway or the acetyl group from acetyl-CoA via either py-
ruvate metabolism or fatty acid degradation. Obesity, highly prevalent
in parts of the world and increasing throughout, is associated with dia-
betes and cardiovascular conditions. Diet-induced obesity can alter
chromatin modiﬁcation in rodents and as mentioned above, there are
epigenetic alterations in T2D donors [60, also 5, 24]. Differential gene
expression and associated changes in chromatin modiﬁcation are ob-
served in obese prone (OP) versus obese resistant (OR) rats fed a
high-fat (HF) diet [61]. But epigenetics and epigenome–environment
connections are also implicated in the host–microbiota relationship
and data increasingly suggest that this is a two-way road. Developmen-
tal programs, such as those of immune cells, are shaped through differ-
ential genes expression; the immune system is key to shaping the
microbiota; microbiota-derived molecules impact on the epigenome
of the host and the resulting functional effects reﬂect back on the envi-
ronment that modulates the microbiota [62]. What is the role of micro-
biota in diabetes?
3.4. Microbiota and Diabetes
The cross-talk between the immune system and microbiota and
the connection between autoimmunity and T1D suggests that the mi-
crobiota likely has a role in the condition. Studies show that there are
differences in gut microbiota, composition and/or function between di-
agnosed and healthy children, although it is not clear if this underlies
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lections [see 6]. Although T1D has long been associated with adaptive
immunity, studies reveal that there is an innate inﬂammatory response
in the biobreeding (BB) rat strain models of T1D and humans with T1D.
It is thought that gutmicrobiotamay have a role in shaping adaptive im-
munity and could extend beyond the gut [see 6]. Changes in gut micro-
biota can result in intestinal permeability and proinﬂammatory
responses, as reported for human and animal models [63].
While the link between T2D and the microbiome may be rather
elusive, its connection to obesity is well evidenced. The composition of
gut microbiota is different between obese-prone (OP) and obese-
resistant (OR) rats, BB diabetes-prone and diabetes resistant (BBDP ver-
sus BB DR) rats and also, between obese mice or human subjects, and
the lean individuals [see 6, 62]. It has to be mentioned that there is di-
versity between themicrobiome of different individuals and even great-
er diversity between the sites the microorganisms occupy [64].
4. Conclusions and Future Directions
4.1. Continuing the Journey
In the previous sections, diabetes-related data, particularly T2D,
were sought starting from selected entry points, navigating between
and from strains, QTLs and genes and further expanding the investigat-
ing range using a few leads and, throughout the journey, employing
several of the available tools. It was one course among others that
could have been followed using the same ‘starting material’ but travel-
ing along different routes.
Wnt signaling, for which TCF7L2 is one of the mediators, besides
the genes downstream of TCF7L2 identiﬁed in pancreatic islets, has
many other targets in many tissues, including components of the Wnt
pathway itself (see the links from the target gene page, in the diagram,
ref [42]). TCF7L2 also controls the expression of preproglucagon (GCG)
in the brain and gut [65]. The processing of GCG gives rise to glucagon
and several other peptides like somatostatin, glucagon-like peptide-1
and -2, all with roles in insulin and glucagon secretion, glucose and
energy homeostasis. Which peptide is expressed where, depends on
the relative levels of processing enzymes PCSK1 and 2, which in the is-
lets, as mentioned, are under TCF7L2 control (and possibly, others).
Could an imbalance in GCG outcomes, whose putative origins may
range from sequence variation to non-coding RNA control, epigenetics,
diet/environment interactions, andmicrobiota, in single and any combi-
nation of them, result in aberrant contributions to glucose levels and hy-
perglycemia? The contribution of glucagon to diabetes, that is glucagon
excess, rather than insulin deﬁciency, has been proposed [16].
It should be mentioned here that rat Tcf7l2, and the exclusively
pancreatic islet expressed Slc30a8, whose variants confer both diabetes
risk and protective effects [46] and whose autoantibodies are detected
in T1D patients [66], have targeted mutations introduced via zinc ﬁnger
nuclease (ZFN) mutagenesis. These are two among many other genes
targeted for knock-out in the PhysGen Knockouts program. The status
of genes and strains, contact and other valuable information, can be
found at the site, available as link from the strain report page or the
‘Custom Rats’ tab on the main home page [Fig. 1, highlighted in
yellow].
Interestingly, besides genes particularly if not uniquely expressed in
beta cells, others appears to be ‘forbidden’, although rather abundantly
expressed in other tissue types [13 and references therein]. Also, the
pancreatic beta cells can dedifferentiate to a progenitor-like state and
are able to convert to other hormone-producing cells. Results from ani-
mal model studies point to the role of Foxo1 in the process, whose grad-
ual loss in the context of progressing T2D can be pathogenic [67]. The
gene is a member of the large forkhead box (FOX) family of transcrip-
tion factors involved in a range of processes, including differentiation.
Themanual disease annotations for Foxo1 point to both T1D and T2D as-
sociations, as well as insulin resistance, heart failure, premature agingand, like TCF7L2, to pancreatic neoplasms. The pathway annotations
via the KEGG pipeline indicate insulin signaling and prostate cancer
pathways while the manual annotations point to transforming growth
factor beta (TGF-beta) SMAD dependent signaling, for which this and
other FOX members are interacting co-factors/co-activators of SMADs.
LikeWnt, TGF-beta SMADdependent signaling is involved in embryonic
development, cell proliferation, differentiation, among other processes.
And while Foxo1 is not one of the culprits in the altered version of the
pathway, the altered TGF-beta SMAD network is associated with pan-
creatic cancer and also, with colorectal cancer pathways. Looking up
the references for the metformin drug pathway, a T2D agent that also
exhibits antineoplastic effects, it appears that, indeed, in diabetic pa-
tients, there is/may be a risk for developing certain types of cancer.
Given the large number of altered pathways in pancreatic cancer [see
diagram at http://rgd.mcw.edu/rgdweb/pathway/pathwayRecord.
html?acc_id=PW:0000626, check Jones et al. in the reference section
of the page, or see 30] and the relatively obscure etiology of T2D, deter-
mining the ‘intersection’ of the two is likely to be a daunting, albeit im-
portant task. Intriguingly, like the dedifferentiating beta cells, the
pancreatic acinar cell—the most abundant cell type and possibly the
cell of origin of pancreatic neoplasms—can, under certain conditions, ac-
quire plastic capabilities, reverting to a progenitor-like state [in 30, ref-
erence 45].
Likely, coding and non-coding elements and variants within either
or both, alongwith themachineries that control transcription and splic-
ing, timely and tissue-speciﬁc responses and adjustments, and the fac-
tors that shape microbiota, are highly intertwined. While tight
interconnectedness can confer robustness to the system as a whole, it
can also promote its failure if perturbations, perhaps at strategic, or
more vulnerable or in some fashion key points, combine in a rever-
berating, and unfortunately, ill-fated mode. And it may be, that the
versatility of the endocrine/exocrine dual-function pancreas, be-
stows upon the speciﬁc pancreatic cells and elements within,
uniquely and highly sensitive qualities that translate into varied
and far-reaching responses, some certainly desired, but some un-
wanted, like the diabetic and neoplasmic conditions. It would be in-
teresting to see what outcomes, the targeted and simultaneous
introduction of perturbations may produce; animal models would
be useful for such an approach.
A large scale meta-analysis of genome-wide association studies
(GWAS) along with 1000 Genomes (1000G) imputation identiﬁes
four new loci, two each for body mass index (BMI) and fasting glucose
(FG), both glycemic and obesity-related traits, and new variants of
established loci. Of the four new loci, the two BMI—ATP2B1 and AKAP6
and one FG locus—RMST, derive from sex-combined analyses, while
the second FG locus—COL26A1 (known as EMID2), is female-speciﬁc
[68]. The risk of T1D is higher if the father is affected whereas for
T2D, the risk is higher if the mother is affected [1]. Interestingly, in the
Non-Obese Diabetic (NOD) mouse model of T1D, the gender bias on
the involvement of gut microbiota tips on the female side [6].
While the results from human and animal models appear to suggest
differences in the gender bias, understanding the role it plays in the
etiology and development of diabetic conditions is deﬁnitely worth
pursuing.
It may be tempting to continue the journey or start a new one. Per-
haps check for gender differences in the values of measurements found
in PhenoMiner records, use the four newly identiﬁed loci in the
imputation-based approach mentioned above, the other genes from
the OLGA list (the Results Set in Fig. 8) or the genes downstream of
TCF7L2, and design the strategy of a new expedition.
Or maybe, at this point, let the interested user design her/his
own journey across the rich data landscape available at RGD, aided by
tools and resources the database offers, following the leads and routes
that curiosity and imagination could spark and, anticipating the won-
ders one might encounter, journeying here through the magnifying
glass.
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A journey through the data RGD offers was initiated using diabetes
as a case study and following a selected route. Other routes could have
been selected, as mentioned above. Other case study choices could
have been made, as the rat has been extensively used as a model for
a range of conditions. The continuous deployment of new disease
portals and of pathway diagram pages, pathway suites and suite net-
works within the Pathway Portal are important aspects of RGD. The
manual disease and pathway annotations for the human, rat and
mouse genes—a distinguishing feature of RGD curation, also provide a
means for targeting the rat genes associated with diseases and/or
pathways for functional annotation using the three vocabularies of
GO. Updates are made at the level of portals and of individual genes. A
recently updated pathway suite network was mentioned in 3.3. Also
relevant to the topic here is the comprehensive update on GLUT4medi-
ated glucose transport, both the pathway and elementswithin. Informa-
tion on new rat strains is deposited in RGD, and more recently on
sequenced strains. Data on new rat QTLs is made available, as the arti-
cles on themare published. Pipelines are developed to bring in data gen-
erated by others. Recent examples include the pipelines for OMIM,
ClinVar and miRGate data import. These and the other RGD pipelines
are run on a weekly basis. New pipelines for importing pathway data
generated by other groups are under development. Tools are developed
to access andmanipulate data in various ways; OLGA is an example of a
recently deployed tool. The biological knowledge is still incomplete and
fragmented, the elements of the biological world are highly
interconnected—these realizations only growwith every newdiscovery.
Even for something like diabetes for which so much research has been
devoted, we are far from fully understating its etiology. However, as
new aspects are uncovered and others could be thought of, having
large repositories of sets of biological data types and data available on
them can aid in the investigation of particular issues. It can also prompt
asking new questions and seeking out new venues for ﬁnding answers.
RGD actively seeks to provide a comprehensive knowledge platform
whose content andmeans to access it can offer a rewarding exploratory
journey to its users.
A new disease portal – Aging & Age-Related Disease Portal, has been
recently released. ThemiRNA gene report pages now provide Cytoscape
format displays showing relationships between validatedmiRNA target
genes and disease or pathway groups to which they are annotated.
Conﬂict of Interest
The authors declare that they have no conﬂict of interest.
Acknowledgments
The RGD project is funded by Grant HL064541 from the National
Heart, Lung, and Blood Institute on behalf of the National Institutes of
Health.
References
[1] Groop L, Pociot F. Genetics of diabetes—are we missing the genes or the disease?
Mol Cell Endocrinol 2014;25:726–39.
[2] Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge.
Lancet Diabetes Endocrinol 2014;2:56–64.
[3] Ahlqvist E, van Zuydam NR, Groop LC, McCarthyMI. The genetics of diabetic compli-
cations. Nat Rev Nephrol 2015;11:277–87.
[4] Eliasson L, Esguerra JLS. Role of non-coding RNAs in pancreatic beta-cell develop-
ment and physiology. Acta Physiol 2014;211:273–84.
[5] Johnson JS, Evans-Molina C. Translational implications of the beta-cell epigenome in
diabetes mellitus. Transl Res 2014;165:91–101.
[6] Tai N, Wong FS, Wen l. The role of gut microbiota in the development of type 1,
type2 diabetes mellitus and obesity. Rev Endocr Metab Disord 2015;16:55–65.
[7] Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety proﬁle of currently avail-
able diabetic drugs. Ochsner J 2014;14:616–32.
[8] Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;17:1709–16.[9] Rena G, Pearson ER, Sakamoto K. Molecular mechanisms or action of metformin: old
or new insights? Diabetologia 2013;56:1898–906.
[10] Authier F, Desbuquois B. Glucagon receptors. Cell Mol Life Sci 2008;65:1880–99.
[11] Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: roles of glucagon
and Glp-1 in health and disease. Physiol Rev 2015;95:513–48.
[12] Eliasson L, Abdulkader F, Braun M, Galvanokins J, Hoppa MB, Rorsman P. Novel as-
pects of themolecular mechanisms of insulin secretion. J Physiol 2008;685:3313–24.
[13] Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic beta-cell identity,
glucose sensing and control of insulin secretion. Biochem J 2015;466:203–18.
[14] Youngren JF. Regulation of insulin receptor function. Cell Mol Life Sci 2007;64:
873–91.
[15] Taniguchi CM. Critical nodes in signaling pathways: insights into insulin action. Nat
Rev Mol Cell Biol 2006;7:85–96.
[16] Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophys-
iologic and therapeutic makeover. J Clin Invest 2012;122:4–12.
[17] Thorens B. Neural regulation of pancreatic islet cell mass and function. Diabetes
Obes Metab 2014(Suppl. 1):87–95.
[18] Klip A, Sun Y, Chiu TT, Foley KP. Signal transduction meets vesicle trafﬁc: the soft-
ware and hardware of GLUT4 translocation. Am J Physiol Cell Physiol 2014;306:
C879–86.
[19] Satoh T. Rho GTPases in insulin-stimulated glucose uptake. Small GTPases 2014.
http://dx.doi.org/10.4161/sgtp.28102.
[20] Montessuit C, Lerch R. Regulation and dysregulation of glucose transport in
cardiomyocytes. Biochim Biophys Acta 2013;1833:848–56.
[21] Zorzano A, Palacin H, Guma A. Mechanisms regulating GLUT4 glucose transport ex-
pression and glucose transport in skeletal muscle. Acta Physiol Scand 2005;183:
43–58.
[22] Ojuka EO, Goyaram V, Smith JAH. The role of CaMKII in regulating GLUT4 expression
in skeletal muscle. Am J Physiol Endocrinol Metab 2012;303:E322–31.
[23] Hart GW, Slawson C, Ramirez-Correa Lagerlof O. Cross talk between O-
GlcNAcylation and phosphorylation: roles in signaling, transcription and chronic
disease. Annu Rev Biochem 2011;80:825–58.
[24] Ma J, Hart GW. Protein O-GlcNAcylation in diabetes and diabetic complications. Ex-
pert Rev Proteomics 2013;10:365–80.
[25] Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB
Life 2012;64:362–9.
[26] Jensen MV, Joseph JW, Ronnbaum SM, Burgess SC, Sherry AD, Newgard CB. Metabol-
ic cycling in control of glucose-stimulated insulin secretion. Am J Physiol Endocrinol
Metab 2008;295:E1287–97.
[27] Hayman GT, Jayaraman P, Petri V, Tutaj M, Liu W, De Pons J, et al. The updated RGD
Pathway Portal utilizes increased curation efﬁciency and provides expanded path-
way information. Hum Genomics 2012. http://dx.doi.org/10.1186/1479-7364-7-4.
[28] Hayman GT et al., in preparation.
[29] Petri V, Jayaraman P, Tutaj M, Hayman GT, Smith JR, De Pons J, et al. The pathway
ontology—updates and applications. J Biomed Semant 2014. http://dx.doi.org/10.
1186/2041-1480-5-7.
[30] Petri V, Hayman GT, Tutaj M, Smith JR, Laulederkind SJ, Wang SJ, et al. Disease path-
ways at the Rat Genome Database Pathway Portal: genes in context—a network ap-
proach to understanding the molecular mechanisms of disease. Hum Genomics
2014. http://dx.doi.org/10.1186/s40246-014-0017-8.
[31] ShimoyamaM, De Pons J, Hayman GT, Laulederkind SJ, LiuW, Nigam R, et al. The Rat
Genome Database 2015: genomic, phenotypic and environmental variations and
disease. Nucleic Acids Res 2015;43:D743–50.
[32] Laulederkind SJ, Liu W, Smith JR, Hayman GT, Wang SJ, Nigam R, et al. PhenoMiner:
quantitative phenotype curation at the rat genome database. Database (Oxford)
2013. http://dx.doi.org/10.1093/database/bat015.
[33] Wang SJ, Laulederkind SJ, Hayman GT, Petri V, Liu W, Smith JR, et al. PhenoMiner: a
quantitative phenotype database for the laboratory rat, Rattus norvegicus. Applica-
tion in hypertension and renal disease. Database (Oxford) 2015. http://dx.doi.org/
10.1093/database/bau128.
[34] Smith JR, Park CA, Nigam R, Laulederkind SJ, Hayman GT, et al. The clinical measure-
ment, measurementmethod and experimental condition ontologies: expansion, im-
provements and new applications. J Biomed Semant 2013. http://dx.doi.org/10.
1186/2041-1480-4-26.
[35] Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix MH, Bailbé D, et al. The GK
rat beta cell: a prototype for the diseased human beta-cell in type 2 diabetes? Molec
Cell Endocrinol 2009;297:73–85.
[36] Galli J, Fakhrai-Rad H, Kamel A, Marcus C, Norgren S, Luthman H. Pathophysiological
and genetic characterization of the major diabetes locus in GK rats. Diabetes 1999;
48:2463–70.
[37] Lin JM, Ortsater H, Fakhrai-Rad H, Galli J, Luthman H, Bergsten P. Phenotyping of
individual pancreatic islets locates genetic defects in stimulus secretion cou-
pling to Niddm1i within the major diabetes locus in GK rats. Diabetes 2001;
50:2737–43.
[38] Granhall C, Rosengren AH, Renstrom E, Luthman H. Separately inherited defects in
insulin exocytosis and beta-cell glucose metabolism contribute to type 2 diabetes.
Diabetes 2006;55:3494-2500.
[39] Granhall C, Park HB, Fakhrai-Rad H, Luthman H. High resolution quantitative train
locus analysis reveals multiple diabetes susceptibility loci mapped to intervals
b800 kb in the species-conserved Niddm1i of the GK rat. Genetics 2006;174:
1565–72.
[40] Hermsen R, de Ligt J, Spee W, Blokzijl F, Schäfer S, Adami E, et al. Genomic landscape
of rat strain and substrain variation. BMC Genomics 2015;16:357.
[41] Atanur SS, Diaz AG, Maratou K, Sarkis A, Rotival M, Game L, et al. Genome sequenc-
ing reveals loci under artiﬁcial selection that underlie disease phenotypes in the lab-
oratory rat. Cell 2013;154:691–705.
48 V. Petri et al. / Computational and Structural Biotechnology Journal 14 (2016) 35–48[42] http://rgd.mcw.edu/rgdweb/pathway/pathwayRecord.html?processType=view
&species=Rat&acc_id=PW:0000201.
[43] Zhou Y, Park SY, Su J, Bailey K, Ottosson-Laakso E, Shcherbina L, et al. TCF7L2 is a
master regulator of insulin production and processing. Hum Mol Genet 2014;23:
6419–31.
[44] Kaneto H, Matsuoka T. Role of pancreatic transcription factors in maintenance of
mature beta-cell function. Int J Mol Sci 2015;16:6281–97.
[45] Lemaire K, Chimienti F, Schuit F. Zinc transporters and their role in the pancreatic
beta-cell. J Diabet Invest 2012;3:202–11.
[46] Davidson HW, Wenzlau JM, O'Brien RM. Zinc transporter 8 (ZnT8) and beta cell
function. Trends Endocrinol Metab 2014;25:415–24.
[47] Hansson O, Zhou Y, Renstrom E, Osmark P. Molecular function of TCF7L2: conse-
quences of TCF7L2 splicing for molecular function and risk for type 2 diabetes.
Curr Diab Rep 2010;10:444–51.
[48] Li X. miR-375, a microRNA related to diabetes. Gene 2014;533:1–4.
[49] Stroynowska-Czerwinska A, Fiszer A, Krzyzosiak WJ. The panorama of miRNA-
mediated mechanisms in mammalian cells. Cell Mol Life Sci 2014;71:2253–70.
[50] Yang L, Froberg JE, Lee JT. Long noncoding RNAs: fresh perspectives into the RNA
world. Trends Biochem Sci 2014;39:35–43.
[51] Kornfeld JW, Bruning JC. Regulation of metabolism by long, non-coding RNA. Front
Genet 2014. http://dx.doi.org/10.3389/fgene.2014.00057.
[52] MaoY Mohan R, Zhang S, Tang X. miRNAs as pharmacological targets in diabetes.
Pharmacol Res 2013;75:37–47.
[53] Dehwah MA, Xu A, Huang Q. MicroRNA and type 2 diabetes/obesity. J Genet Geno-
mics 2012;39:11–8.
[54] Andres-Leon E, Gonzalez Pena D, Gomez-Lopez G, Pisano DG. miRGate: a curated da-
tabase of human, mouse and rat miRNA-mRNA, targets. Database (Oxford) 2015.
http://dx.doi.org/10.1093/database/bav035.
[55] Steiner DJ, Kim A, Miller K, Hara M. Pancreatic islets plasticity: interspecies compar-
ison of islet architecture and composition. Islets 2010;2:135–45.[56] Esguerra JLS, Eliasson L. Functional implications of lncRNA in the pancreatic islets of
Langerhans. Front Genet 2014;5:1–9.
[57] Moran I, Akerman I, van de Bunt M, Xie R, Benazra M, Nammo T, et al. Human beta-
cell transcriptome analysis uncovers lncRNAs that are tissue-speciﬁc, dynamically
regulated, and abnormally expressed in type 2 diabetes. Cell Metab 2012;16:
435–48.
[58] http://rgd.mcw.edu/wg/pathway/gene-expression-and-regulation-pathway-suite-
network#gerpsn.
[59] Ronn T, Ling C. DNA methylation as diagnostic and therapeutic target in the battle
against type 2 diabetes. Epigenomics 2015;7:451–60.
[60] Schones DE, Leung A, Natarajan R. Chromatinmodiﬁcations associated with diabetes
and obesity. Arterioscler Thromb Vasc Biol 2015;35:1557–61.
[61] Zhang X, Zhou D, Strakovsky R, Zhang Y, Pan YX. Hepatic cellular senescence path-
way genes are induced through histone modiﬁcations in a diet-induced obese rat
model. Am J Physiol Gastrointest Liver Physiol 2012;302:G558–64.
[62] Alenghat T. Epigenomics and the microbiota. Toxicol Pathol 2014;43:101–6.
[63] Cabrera SM, Henschel AM, Hessner MJ. Innate inﬂammation in type 1 diabetes.
Transl Res 2015. http://dx.doi.org/10.1016/j.trsl.2015.04.011.
[64] Muszer M, Noszczynska M, Kasperkiewicz K, Skurnik M. Human microbiome: when
a friend becomes an enemy. Arch Immunol Ther Exp (Warsz) 2015;63:287–98.
[65] ShaoW, Wang D, Chiang YT, Ip W, Zhu L, Xu F, et al. The Wnt signaling pathway ef-
fector TCF7l2 controls gut and brain preproglucagon, expression and glucose ho-
meostasis. Diabetes 2013;62:789–800.
[66] Kawasaki E. Type 1 diabetes and autoimmunity. Clin Pediatr Endoctrinol 2014;23:
99–105.
[67] Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta-cell dedifferentiation as
mechanism of diabetic beta-cell failure. Cell 2012;150:1223–34.
[68] HorikoshiM,Mägi R, van der BuntM, Surakka I, Sarin AP, Mahajan A, et al. Discovery
and ﬁne-mapping of glycaemic and obesity-related trait loci using high-density im-
putation. PLoS Genet 2015. http://dx.doi.org/10.1371/journal.pgen.1005230.
